LAUSR

Experts’ summary: This publication [1] addresses the long-awaited data on patients diagnosed with prostate cancer in the prostate-specific antigen (PSA) era that were randomized between active monitoring (n = 545), radical prostatectomy (+/– lymph node dissection; n = 553), and radiotherapy (plus 3–6 mo androgen deprivation therapy; n = 545). In total, 1643 out of 2664 patients agreed to be randomized. The primary outcome on prostate cancer mortality was not different between the three arms at a median follow-up of 10 yr. However, the incidence of metastases was higher in the active monitoring group.